BRAF and cancer: The aberrant activation of the classical MAPK pathway with extracellular signal-regulated kinase (ERK) as the terminal kinase is a frequent event in human cancer and is often the result of activating mutations in the oncogenes; BRAF (7%; Davies et al., 2002) and RAS (15–30%; Bos, 1989) based on analyses of all cancer types.